Xenon Pharmaceuticals Inc.
XENE
$55.00
-$0.78-1.40%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | 0.92% | 13.81% | |||
| Gross Profit | -0.92% | -13.81% | |||
| SG&A Expenses | 7.94% | 14.45% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 2.33% | 13.94% | |||
| Operating Income | -2.33% | -13.94% | |||
| Income Before Tax | -0.14% | -16.08% | |||
| Income Tax Expenses | -577.88% | -20.53% | |||
| Earnings from Continuing Operations | 2.81% | -15.80% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 2.81% | -15.80% | |||
| EBIT | -2.33% | -13.94% | |||
| EBITDA | -2.37% | -14.07% | |||
| EPS Basic | 10.85% | -14.53% | |||
| Normalized Basic EPS | 8.14% | -14.81% | |||
| EPS Diluted | 10.85% | -14.53% | |||
| Normalized Diluted EPS | 8.14% | -14.81% | |||
| Average Basic Shares Outstanding | 9.01% | 1.11% | |||
| Average Diluted Shares Outstanding | 9.01% | 1.11% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||